Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis’ Insulin Pen Prone To Medication Errors – ISMP

This article was originally published in The Pink Sheet Daily

Executive Summary

OptiClik insulin delivery system’s digital display, when incorrectly oriented, may cause overdosing or subtherapeutic dosing, according to Medication Safety Alert.

You may also be interested in...

Physician Drug Samples’ Impact On Patient Safety Needs Study, IoM Says

The Institute of Medicine report on medication errors also recommends FDA issue guidances this year on packaging and drug naming.

Aventis Lantus Approved For Use With Insulin Delivery Device

The OptiClick reusable “pen” injection system will be used with insulin products Lantus, Apidra; both had been approved for subcutaneous injection. Aventis has not announced its launch plans for OptiClick.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts